Corcept Therapeutics' recent surge in stock price is attributed to the success of its drug Korlym, which is the only drug currently marketed by the company and is approved for treating Cushing's syndrome. The strong demand for Korlym is a driving force behind the company's growth in the market. Additionally, the impending new drug application for relacorilant, Corcept's lead candidate for treating Cushing's syndrome, is anticipated to further bolster the company's position in the pharmaceutical industry.
Despite the positive stock performance and growth prospects, it is crucial to monitor Corcept's upcoming quarterly earnings report, where earnings of $0.26 per share and revenues of $171.04 million are expected. These figures represent a year-over-year change and would provide more insights into the company's financial health. In the volatile stock market, it is emphasized that continuous evaluation of the stock's performance, particularly in relation to earnings estimate revisions, is essential to gauge the future trajectory of the share price.
In comparison to Corcept, another player in the medical-drugs industry, Zoetis, also experienced a modest increase in its stock price in the last trading session. The company's stock, priced at $196.48, is showing positive growth trends, with earnings per share estimates rising by 7.4% compared to the previous year. Zoetis, with a Zacks Rank of #2 (Buy), represents a strong contender in the industry.